Insider selling at Regal Rexnord, particularly below current share price, is seen as a negative signal. The absence of insider buying in the last three months and significant selling in the last quarter paints a less positive picture. Despite some alignment due to insider ownership, caution is advised before purchasing shares.
Despite Regal Rexnord's strong performance and revenue growth, its projected growth is lower than the industry average. Coupled with an average P/S ratio, the stock may be overvalued and at risk of a price decline.
Despite a drop in EPS, Regal Rexnord is positively received, possibly due to revenue growth and insider purchases. However, recent gains have been modest, with shareholders gaining just 2.0%, including dividends.
Regal Rexnord's dividend sustainability is doubtful due to last year's unprofitability. Covering dividends by free cash flow raises questions for long-term suitability if profits aren't steady. It may not be ideal for long-term investors seeking dividends.
Despite recent insider purchases signifying positives, insider John Avampato's selling activity is viewed negatively. The company insiders display a fair level of share ownership, aligning with smaller shareholders. Independent Director Theodore Crandall's purchase fuels confidence, yet past year's transaction history lacks consistent insider enthusiasm.
Investors appear unfazed by the EPS drop, hinted at by the share price growth. The modest 1.2% dividend yield doesn't seem a major allure. This implies investors are more optimistic about future growth than current profitability metrics.
Regal Rexnord股票讨论区
目前市盈率35,估值没有吸引力。
专栏US Top Gap Ups and Downs on 12/2: PATH, CS, ZS, PYPL and More
Gap Ups
1. $Samsara(IOT.US)$ - up 16.75%
2. $UiPath(PATH.US)$ - up 7.15%
3. $Credit Suisse(CS.US)$ - up 2.88%
4. $Sendas Distributor(ASAI.US)$ - up 0.38%
5. $费森尤斯医疗(FMS.US)$ - up 0.31%
Gap Downs
1. $Veeva Systems(VEEV.US)$ - down 3.86%
2. $韩国电力(KEP.US)$ -...
专栏Today's Pre-Market Stock Movers: ORCL, RENT, U, AKRO and More
In reaction to earnings/guidance:
• $Planet Labs PBC(PL.US)$ +11.3%,$Core & Main(CNM.US)$ +6.1%,$Regal Rexnord(RRX.US)$ +2% (reaffirms outlook),$甲骨文(ORCL.US)$ +1.6%
Other news:
• $Akero Therapeutics(AKRO.US)$ +93.2% (reports Phase 2b HARMONY Study)
• $Akouos(AKUS.US)$ +10.3% (FDA clears IND application to initiate a Phase 1/2 first in human pediatric clinical trial of AK-OTOF)
• $Catalyst Pharmaceuticals(CPRX.US)$ +7.7...
暂无评论